Portland, ORNCT07690436Now EnrollingIRB Ready

Transthyretin Amyloid Cardiomyopathy Clinical Trial in Portland, OR

Access cutting-edge transthyretin amyloid cardiomyopathy treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access transthyretin amyloid cardiomyopathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related transthyretin amyloid cardiomyopathy treatment provided free

Apply for This Portland Location

Check if you qualify for this transthyretin amyloid cardiomyopathy clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Transthyretin Amyloid Cardiomyopathy Study in Portland

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

1\. Participant must be 18 years and older at the time of signing the informed consent form.
2\. Participants with either of the following:
\- Positive ATTR-CM cases: Participants with a clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) with amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining, or DPD-Tc, PYP-Tc, or HMDP-Tc scintigraphy with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio.
\- Control population: Participants with a clinical diagnosis of guideline-directed medical therapy-directed heart failure (HF) and either:
a) Subgroup A: Definitively excluded ATTR-CM amyloidosis: negative cardiac or non-cardiac tissue biopsy for amyloid, or negative technetium scintigraphy within the past 2 years.
b) Subgroup B: Low probability of ATTR-CM amyloidosis, not definitively excluded: absence of amyloid-suggestive features on echocardiography (ECHO), electrocardiography (ECG), or cardiac magnetic resonance imaging (MRI) within the past 2 years, with documented clinical assessment indicating HF etiology unlikely attributable to amyloidosis; no amyloid-specific testing (technetium scintigraphy or biopsy) performed.
3\. Participant or legally authorized representative (LAR) must sign the informed consent form.

Exclusion Criteria

1\. Any known eye condition that may preclude clear imaging of the retina.
2\. Any known history of amyloid light-chain (AL) amyloidosis.
3\. Any ocular surgery that, in the opinion of the investigator, makes participation in the study undesirable.
4\. Any medical condition that, in the opinion of the investigator, makes participation in the study undesirable, for example, if the participant is critically unwell or requires ongoing emergency treatment.
5\. Involvement in the planning and/or conduct of the study.
6\. In the opinion of the investigator, the participant is unlikely to comply with study procedures, restrictions, and requirements.
7\. Previous enrollment in the present study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT07690436) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Transthyretin Amyloid Cardiomyopathy Treatment Options in Portland, OR

If you're searching for transthyretin amyloid cardiomyopathy treatment options in Portland, OR, this clinical trial (NCT07690436) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced transthyretin amyloid cardiomyopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all transthyretin amyloid cardiomyopathy clinical trials near you to find additional studies recruiting in your area.

More Cardiomyopathy Trials in Portland, OR

See all cardiomyopathy clinical trials recruiting in Portland — not just this study.

Browse Cardiomyopathy Trials in Portland →

Browse More Trials by Condition

Cardiomyopathy TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAmyloidosis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR